Dan Sheeran said AI is helping eliminate some of the pharmaceutical industry’s biggest bottlenecks, including finding the right drug and proving it works in trials. That’s the pitch from the top: faster machines, fewer delays, and a smoother pipeline for companies that already control who gets treatment and when. For patients, Sheeran said, that means "years of waiting for a treatment that may already be in the development pipeline but hasn't made it through discovery, clinical trials and approval."
Who Gets Stuck Waiting
The people at the bottom of the chain don’t get to decide the pace. They wait while pharmaceutical companies, regulators and research systems move at the speed of paperwork, profit and institutional caution. Sheeran, vice president and general manager of Healthcare and Life Sciences at Amazon Web Services, said scientists must search through a near-infinite chemical space for molecules that are both effective and safe, and that the process has historically been manual, sequential and slow. That slow grind is exactly what patients are told to endure while the apparatus sorts itself out.
Sheeran said, "AI agents can now propose candidate molecules, predict their properties, and learn from each round of experiments to sharpen the next round automatically." He said AI is already helping at this early stage. Genentech built an AI agent that searches 38 million biomedical papers to identify drug targets and validate biomarkers, automating more than 43,000 hours of manual research each year, Sheeran said. Sanofi created a lab-in-the-loop system in which AI agents design molecules, plan synthesis, run experiments and learn from the results in a continuous cycle, and Sheeran said the result is discovery work that can be compressed into weeks rather than years. He also said virtual models can test how the human body reacts to molecules before physical lab work begins.
The Administrative Maze
Ram Yalamanchili, founder and CEO of Tilda Research, said shortening the time required to run clinical trials is another way technology helps patients receive new medications sooner. He said, "Running a clinical trial in the U.S. typically costs tens of millions of dollars and takes several years to complete." That’s the price of a system built around layers of oversight, documentation and control, where the burden of compliance falls on researchers and the waiting falls on everyone else.
Yalamanchili said the work involves getting research sites activated, collecting and reviewing regulatory documents, resolving missing information, coordinating with research sites and vendors, and keeping thousands of records accurate and inspection-ready. Tilda Research's AI Teammates platform reduced work expected to take six months to less than eight weeks, he said. He added, "AI isn't shortening how long you need to monitor a patient's response to a drug, and it shouldn’t, [but] what it does is remove the delays caused by human bottlenecks in the administrative machinery around a trial so trials can start faster, run with fewer errors, and move through regulatory documentation faster — which does, in aggregate, move a drug toward patients sooner."
That quote lays out the whole machine in plain language. The delays aren’t just scientific. They’re bureaucratic, institutional and deeply managed.
Factories, Forecasts and the Supply Chain
The article said AI can also optimize manufacturing and improve supply chain forecasting. Using digital twins, or virtual replicas of factories, manufacturers can monitor production lines to identify slowdowns and bottlenecks. Sensors can flag the likelihood of equipment wear before breakdowns happen, helping minimize costly factory downtime. AI can sift through massive biomedical datasets in seconds to find promising drug candidates. It can also help companies better predict who needs medications, where they are needed and when demand may surge, reducing shortages and overstocked medications that may expire before they are used. During delivery, AI-powered monitoring systems can track temperature-sensitive vaccines to prevent spoilage en route to a destination before they reach patients.
That’s the corporate promise: fewer spoiled vaccines, fewer broken machines, fewer wasted doses, fewer delays. The people making the decisions still sit at the top of the chain, while everyone else gets the efficiency story.
The piece said AI ushers in massive benefits across the pharmaceutical ecosystem, from drug makers and manufacturers to hospitals, clinics and pharmacies, by removing inefficiencies that slow progress. It said the ultimate benefit is getting safe, effective medicines into the hands of those who need them faster. That’s the official line, anyway. Faster for whom, and under whose control, remains the real question.
A separate New York Times opinion piece, "The Search for New Cures Is Broken," argued that translating laboratory discoveries into clinical treatments remains a major hurdle and that the drug development system is plagued by structural inefficiencies that slow progress toward cures. Taken together, the pieces present a tension between optimism about AI-driven acceleration and a critique of foundational flaws in the cures and drugs pipeline. The system keeps promising speed, while the deeper machinery of access, approval and control stays intact.